Immunomodulatory ADCs for Localized STING Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing STING agonists for immunotherapy have poor pharmacological properties, including enzymatic degradation and poor bioavailability, leading to systemic cytokine induction and off-target toxicity.
Innovation Solution
Development of antibody-drug conjugates (ADCs) that conjugate STING agonists to antigen-binding proteins via succinimide or hydrolyzed succinimide linkages to cysteine residues, allowing localized immune response targeting with reduced off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleotide-based STING agonists are used, then anti-tumor immune response is activated, but systemic cytokine induction and off-target toxicity occur
Solution Approach 1:
The patent segments the STING agonist delivery system into two functional components: (1) an antibody component that provides tumor targeting and localization, and (2) a STING agonist component that provides immune activation. This segmentation allows the immune activating function to be separated from the harmful systemic effects, as the agonist is only activated at the tumor site where the antibody binds.
Solution Approach 2:
The patent applies local quality by creating a conjugate where the STING agonist is attached to an antibody that specifically binds to tumor-associated antigens. This ensures that the immune activating effect is localized to the tumor microenvironment rather than being distributed systemically throughout the body, thereby reducing off-target toxicity while maintaining anti-tumor efficacy.
2Reliability
If nucleotide-based STING agonists are administered systemically, then immune response is activated, but poor bioavailability and pharmacokinetics occur
Solution Approach 1:
The patent uses an antibody as an intermediary carrier that facilitates the delivery of the STING agonist to the tumor site. The antibody serves as a mediator that improves bioavailability by protecting the agonist from degradation and enhancing pharmacokinetics through receptor-mediated endocytosis, allowing the agonist to reach its target more effectively.
Solution Approach 2:
The patent creates a composite molecule combining the antibody (providing targeting and pharmacokinetic properties) with the STING agonist (providing immune activation). This composite structure leverages the advantages of both components: the antibody's improved bioavailability and pharmacokinetics combine with the agonist's immune activating capability to achieve effective tumor targeting.
3Object-affected harmful factors
If STING agonists are conjugated to antibodies via succinimide linkages, then localized immune response is achieved, but conjugation complexity increases
Solution Approach 1:
The patent utilizes parameter changes in the conjugation chemistry by employing succinimide linkages that form stable covalent bonds between the antibody and STING agonist. This chemical parameter change creates a stable, irreversible conjugate that maintains the localized immune response benefit while providing sufficient stability for pharmacological application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADCs provide selective, localized immune activation with reduced systemic immune activation, enhancing anti-tumor efficacy while minimizing adverse effects.
Implementation Method 1
conjugated to the antigen-binding protein or antigen-binding fragment thereof via a succinimide or hydrolyzed succinimide covalently linked to a sulfur atom of a cysteine residue
Data Source
AI summary
The present disclosure provides, inter alia, antibody-drug conjugates that are useful in treating various diseases such as cancer.